AbbVie will acquire Apogee Therapeutics for $10.9B, adding clinical-stage antibody programs in atopic dermatitis and asthma to strengthen its immunology and respiratory pipeline.
Written By: Samiksha Jadhav, BPharm
Reviewed By: Pharmacally Editorial Team
AbbVie will acquire Apogee Therapeutics in an all-cash transaction valued at approximately $10.9 billion, bringing a pipeline of clinical-stage immunology and respiratory disease assets into its portfolio. Under the agreement, Apogee shareholders will receive $135.11 per share in cash. Both companies’ boards have approved the deal, which is expected to close in the third quarter of 2026, pending shareholder and regulatory approvals.
The acquisition adds several antibody-based programs targeting inflammatory and immune-mediated diseases, with a particular focus on atopic dermatitis (AD) and asthma. AbbVie expects the transaction to strengthen its leadership in immunology while broadening its presence in respiratory medicine.
Transaction Overview
Apogee’s portfolio includes multiple clinical-stage candidates targeting validated inflammatory pathways. The acquisition complements AbbVie’s existing immunology franchise and adds new growth opportunities in dermatology and respiratory diseases, two of the largest markets in immune-mediated disorders.
The proposed transaction is expected to become accretive to AbbVie’s adjusted diluted earnings per share beginning in 2032, reflecting the company’s long-term confidence in the commercial potential of Apogee’s pipeline.
Lead Asset: IL-13 in Atopic Dermatitis
Apogee’s most advanced program is zumilokibart (APG777), a half-life extended monoclonal antibody that blocks interleukin-13 (IL-13), a key cytokine involved in type 2 inflammation. IL-13 plays a central role in the development of atopic dermatitis and several other allergic and inflammatory diseases.
Despite the availability of biologic therapies, many patients with moderate-to-severe atopic dermatitis continue to experience persistent itching and incomplete skin clearance. Less frequent dosing also remains an important unmet need in long-term disease management.
In a Phase 2 trial, approximately two-thirds of patients treated with zumilokibart achieved significant skin clearance after 16 weeks of therapy. The study also reported meaningful improvements in itch reduction and overall disease control. Longer-term follow-up supported maintenance dosing schedules as infrequent as once every three months or twice yearly.
The ability to maintain disease control with quarterly or twice-yearly dosing could reduce treatment burden and improve long-term treatment adherence for patients requiring chronic therapy.
The safety profile was consistent with other therapies targeting the IL-13 pathway, with no major new safety concerns reported.
Respiratory Expansion via Asthma Combination
Beyond atopic dermatitis, Apogee has developed a broader portfolio of antibodies targeting multiple validated inflammatory pathways.
One of the most notable programs is APG273, a combination of zumilokibart and APG333, a long-acting antibody targeting thymic stromal lymphopoietin (TSLP). TSLP acts upstream in the inflammatory cascade and is considered a key trigger of airway inflammation in asthma.
Phase 1 data showed that APG333 maintained biological activity and suppressed type 2 inflammatory biomarkers for up to six months following administration. Interim Phase 1b results with zumilokibart in asthma further supported the development of APG273 as a potentially long-acting treatment requiring only quarterly or twice-yearly injections.
Strategic Significance
“For more than two decades, AbbVie has led and shaped the field of immunology,” said Robert A. Michael, chairman and chief executive officer of AbbVie. He stated that Apogee’s pipeline adds differentiated clinical-stage assets in atopic dermatitis and asthma, strengthening AbbVie’s immunology leadership and supporting the development of new treatment options for patients with inflammatory diseases.
Michael Henderson, M.D., chief executive officer of Apogee, said the transaction reflects the strength of the company’s scientific strategy and the progress made advancing zumilokibart and its broader pipeline. He added that AbbVie’s global development and commercialization capabilities could help maximize the potential of these programs and expand their impact for patients worldwide.
Regulatory Path Forward
The transaction remains subject to regulatory review and approval by Apogee shareholders. If completed as expected in the third quarter of 2026, AbbVie will gain full ownership of Apogee’s clinical-stage pipeline, including zumilokibart and APG273.
AbbVie is expected to prioritize late-stage development of zumilokibart in atopic dermatitis while advancing respiratory programs that could further expand its immunology franchise and strengthen its position in inflammatory diseases over the coming decade.
Reference
AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio – Jun 22, 2026
AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio | Apogee Therapeutics, Inc.
About the Writer
Samiksha Vikram Jadhav (LinkedIn) is a B. Pharm graduate with a strong academic foundation in pharmaceutical sciences, pharmacology, and drug development. She specializes in pharma market research, with a focused interest in mergers and acquisitions, strategic partnerships, and global pharma and biotech deals. Her work centers on analyzing industry transactions, market positioning, and business strategies, translating complex developments into clear, accurate, and insightful scientific and commercial reporting.